Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To use a pragmatic phase II randomized controlled trial to compare two standardized bundles of usual care for postoperative pain management to reduce the initial discharge prescription opioid volume. SECONDARY OBJECTIVE: I. To assess which pragmatic arm improves aspects of postoperative recovery including 30-day, 3-month, and 1-year opioid use, patient symptom inventory at those time points, hospital measures including length of stay and inpatient pain scores. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. ARM II: Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery. After completion of study treatment, patients are followed up at 1, 3, and 12 months after the surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04189783
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 8, 2020
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03838718 - REtroperitoneal SArcoma Registry: an International Prospective Initiative
Enrolling by invitation NCT05844813 - Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma Phase 4
Terminated NCT00901836 - Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma N/A
Completed NCT05044624 - Retroperıtoneal Soft-Tıssue Sarcomas N/A
Completed NCT04225494 - Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas
Active, not recruiting NCT03792867 - Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma N/A
Not yet recruiting NCT06025747 - Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma Phase 1
Active, not recruiting NCT04224948 - The PET- Retroperitoneal Sarcoma Study N/A
Recruiting NCT04031677 - Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma Phase 3
Recruiting NCT05224934 - Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma Phase 2
Completed NCT03877588 - Nutritional Status in Retroperitoneal Sarcoma. N/A
Completed NCT02384473 - Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma Early Phase 1
Withdrawn NCT05302570 - Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS Phase 2
Recruiting NCT01659203 - Proton or Photon RT for Retroperitoneal Sarcomas Phase 1/Phase 2
Recruiting NCT05631379 - Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma
Recruiting NCT06327477 - Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma Phase 1/Phase 2